Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 9/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19286622 | 0.85 | LTA4H (0.36) | LTA4HCHRNA7CHRNA10CHRNA9KCNJ1 | |
| SCHEMBL16383003 | 0.81 | HPGDS (0.43) | LTA4HCHRNA7CHRNA10CHRNA9HPGDS | |
| SCHEMBL8239613 | 0.80 | LTA4H (0.50) | LTA4HCHRNA7CHRNA10CHRNA9KCNJ1 | |
| SCHEMBL722557 | 0.79 | LTA4H (0.64) | LTA4HCHRNA7CHRNA10CHRNA9KCNJ1 | |
| SCHEMBL3628598 | 0.77 | LTA4H (0.47) | LTA4HCHRNA7CHRNA10CHRNA9KCNJ1 | |
| SCHEMBL17254244 | 0.77 | KCNJ1 (0.49) | LTA4HCHRNA7CHRNA10CHRNA9KCNJ1 | |
| SCHEMBL28320605 | 0.77 | LTA4H (0.62) | LTA4HCHRNA7CHRNA10CHRNA9KCNJ1 | |
| SCHEMBL28257875 | 0.77 | LTA4H (0.62) | LTA4HCHRNA7CHRNA10CHRNA9KCNJ1 | |
| SCHEMBL28362996 | 0.77 | LTA4H (0.62) | LTA4HCHRNA7CHRNA10CHRNA9KCNJ1 | |
| SCHEMBL15018654 | 0.77 | LTA4H (0.50) | LTA4HCHRNA7CHRNA10CHRNA9KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-9745331-B2 | Therapeutic bisphosphonates | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745331-B2 | Therapeutic bisphosphonates | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9416149-B2 | Methods to modulate Rac1 import and to treat pulmonary fibrosis | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150322099-A1 | THERAPEUTIC BISPHOSPHONATES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150005261-A1 | METHODS TO MODULATE RAC1 IMPORT AND TO TREAT PULMONARY FIBROSIS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | LTA4H 1445/4885CHRNA7 4860/4885CHRNA10 4862/4885 |
| US-20150005261-A1 | METHODS TO MODULATE RAC1 IMPORT AND TO TREAT PULMONARY FIBROSIS | RHOT2, RHOA, RAC1 | LTA4H 1413/4885CHRNA7 4309/4885CHRNA10 4133/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | LTA4H 1445/4885CHRNA7 4860/4885CHRNA10 4862/4885 |
| US-20150322099-A1 | THERAPEUTIC BISPHOSPHONATES | PPA1, GGPS1, FDPS | LTA4H 1159/4885CHRNA7 4832/4885CHRNA10 4836/4885 |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | LTA4H 1445/4885CHRNA7 4860/4885CHRNA10 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.